Keyphrases
Type 1 Diabetes Mellitus (T1DM)
100%
Type I Diabetes
100%
Islet Autoimmunity
88%
Type 2 Diabetes Mellitus (T2DM)
86%
COVID-19 Pandemic
62%
Pediatric Patients
59%
Early-onset Type 2 Diabetes
55%
Short Stature
53%
Diabetes
52%
A1 Receptor
44%
Young People
44%
Empagliflozin
44%
Growth Hormone Treatment
44%
Medical Society
44%
Placebo
44%
Growth Hormone
44%
Obesity Prevalence
44%
Individuals at Risk
44%
Glucagon-like
44%
Dipeptidyl peptidase-4 (DPP-4)
44%
Gender Bias
44%
Phase II Trial
44%
Provider Perspectives
44%
Receptor Agonist
44%
Intellectual Disability
44%
Mindfulness-based Interventions
44%
Randomized Double-blind
44%
Facial Dysmorphism
44%
Peruvian
44%
Learning Experience
44%
Medical Education
44%
Patients with Diabetes
44%
Minority Adolescents
44%
Islet Development
44%
Water Drinking
44%
Autoantibodies
44%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
44%
Pathogenic Variants
44%
COVID-19 Pandemic Impact
44%
Patients with Obesity
44%
Remote Learning
44%
Promoting Physical Activity
44%
Diabetes Management
37%
Metabolic Decompensation
29%
Peru
26%
COVID-19
23%
Diabetes Prevention
23%
Parental Diabetes
22%
Discovery of Insulin
22%
Demographic Data
22%
Medicine and Dentistry
Maturity Onset Diabetes of the Young
83%
Pediatrics Patient
59%
Diabetes
53%
Insulin Dependent Diabetes Mellitus
48%
Patient with Diabetes
44%
Linagliptin
44%
Empagliflozin
44%
COVID-19
44%
Glucagon-Like Peptide-1 Agonist
44%
Patient with Obesity
44%
Physical Activity
44%
Metabolic Dysfunction-Associated Steatotic Liver Disease
44%
Pediatrics
21%
Clinical Research
14%
Impaired Glucose Tolerance
14%
Pediatric Endocrinologist
11%
Diabetes Prevention
11%
Infection
8%
Autoantibodies
8%
Pediatric Endocrinology
8%
Liraglutide
8%
Diabetic Ketoacidosis
8%
Body Mass Index
8%
Health Care Provider
8%
Pediatric Obesity
8%
Cell Function
7%
Genetic Risk
7%
Randomized Clinical Trial
7%
Meta-Analysis
7%
Beta Cell
7%
Microangiopathy
7%
Growth Hormone
7%
Lung
7%
Nutrition Assessment
7%
Medical Nutrition Therapy
7%